Table 5.
Number (percentage) of adverse effects occurring at least 5% more often in patients taking rivastigmine than in patients taking placebo or occurring with an incidence significantly different from placebo
| Adverse effect | Rivastigmine groups
|
Placebo (n=239) | ||
|---|---|---|---|---|
| Higher dose* (n=242) | Lower dose (n=242) | |||
| Nausea | 121 (50) | 41 (17)* | 23 (10) | |
| Vomiting | 82 (34) | 19 (8) | 14 (6) | |
| Dizziness | 48 (20) | 25 (10) | 17 (7) | |
| Headache | 45 (19) | 16 (7) | 18 (8) | |
| Diarrhoea | 40 (17) | 23 (10) | 21 (9) | |
| Anorexia | 34 (14) | 8 (3) | 4 (2) | |
| Abdominal pain | 29 (12) | 11 (5) | 7 (3) | |
| Fatigue | 23 (10) | 5 (2) | 6 (3) | |
| Malaise | 23 (10) | 3 (1) | 5 (2) | |
*
P<0.05 compared with placebo (pairwise comparison based on Fisher’s exact test).